PharmaCyte Biotech, Inc. (PMCB) Stock

Healthcare · Biotechnology · Member of Other US Stocks

PharmaCyte Biotech, Inc. (PMCB) closed at USD 0.35 on 2026-10-14, a change of -64.5 % over the past year, with a market capitalization of USD 3.84M.

PharmaCyte Biotech, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

PharmaCyte Biotech, Inc. key figures

Previous close

USD 0.35 (2026-10-14)

1-year change

-64.5 %

Market cap

USD 3.84M

Enterprise value

USD -24.79M

P/E ratio (trailing)

-0.16

P/E ratio (forward)

-0.94

EPS (trailing)

-2.31

EPS (forward)

-0.38

PEG ratio

n/a

Price to book

0.14

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.35

Employees

2

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for PharmaCyte Biotech, Inc. and compare it with other stocks.